2320P Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study
Michiel Zietse(Erasmus MC), Frederick W. Thielen(University Medical Center Freiburg), Roelof W. F. van Leeuwen(Erasmus MC), Ron H.J. Mathijssen(Erasmus MC), A. Jager(Erasmus MC Cancer Institute), Leontine E A M M Spierings(Alrijne Ziekenhuis), Jun Hu(Erasmus MC), Esther R van Staveren(Alrijne Ziekenhuis)
Cited by 0
Related Papers
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345
Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
|Clinical Cancer Research|2012|164